|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cefamandole]] |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| | |
| '''Cefamandole''' ([[International Nonproprietary Name|INN]], also known as '''cephamandole''') is a second-generation [[broad-spectrum antibiotic|broad-spectrum]] [[cephalosporin]] [[antibiotic]]. The clinically used form of cefamandole is the [[formate]] [[ester]] '''cefamandole nafate''', a [[prodrug]] which is administered [[wikt:parenteral|parenterally]].
| |
| | |
| Cefamandole is [[List of withdrawn drugs|no longer available]] in the United States.
| |
| | |
| == Adverse effects ==
| |
| The chemical structure of cefamandole, like that of several other cephalosporins, contains an ''N''-methylthiotetrazole (NMTT or 1-MTT) [[side chain]]. As the antibiotic is broken down in the body, it releases free NMTT, which can cause [[hypoprothrombinemia]] (likely due to [[enzyme inhibitor|inhibition]] of the [[enzyme]] [[vitamin K epoxide reductase]])(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by [[disulfiram]] (Antabuse), due to inhibition of [[aldehyde dehydrogenase]].
| |
| | |
| ==Spectrum of Bacterial Susceptibility==
| |
| Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms. | |
| * ''Escherichia coli'': 0.12 μg/mL - 400 μg/mL
| |
| * ''Haemophilus influenzae'': 0.06 μg/mL - >16 μg/mL
| |
| * ''Staphylococcus aureus'': 0.1 μg/mL - 12.5 μg/mL
| |
| <ref>http://www.toku-e.com/Assets/MIC/Cefamandole%20sodium%20salt.pdf</ref>
| |
| | |
| ==Report==
| |
| CO2 is generated during the normal constitution of cefamandole & ceftazidim resulting in explosive like reaction in syringe
| |
| | |
| <ref name=Goldfrank>{{cite book |author=Stork CM |editor=Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.) |title=Goldfrank's toxicologic emergencies |chapter=Antibiotics, antifungals, and antivirals |chapterurl=http://books.google.com/books?id=cvJuLqBxGUcC&pg=PA847 |publisher=McGraw-Hill |location=New York |year=2006 |pages=847 |isbn=0-07-143763-0 |accessdate=2009-07-03}}</ref>
| |
| | |
| | |
| | |
| ==Category==
| |
| | |
| ==US Brand Names==
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ''' [[XXXXX description|Description]]'''
| |
| '''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[XXXXX microbiology|Microbiology]]'''
| |
| '''| [[XXXXX indications and usage|Indications and Usage]]'''
| |
| '''| [[XXXXX contraindications|Contraindications]]'''
| |
| '''| [[XXXXX warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[XXXXX adverse reactions|Adverse Reactions]]'''
| |
| '''| [[XXXXX drug interactions|Drug Interactions]]'''
| |
| '''| [[XXXXX overdosage|Overdosage]]'''
| |
| '''| [[XXXXX clinical studies|Clinical Studies]]'''
| |
| '''| [[XXXXX dosage and administration|Dosage and Administration]]'''
| |
| '''| [[XXXXX how supplied|How Supplied]]'''
| |
| '''| [[XXXXX labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |